Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,014 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumour mutational burden: clinical utility, challenges and emerging improvements.
Budczies J, Kazdal D, Menzel M, Beck S, Kluck K, Altbürger C, Schwab C, Allgäuer M, Ahadova A, Kloor M, Schirmacher P, Peters S, Krämer A, Christopoulos P, Stenzinger A. Budczies J, et al. Among authors: beck s. Nat Rev Clin Oncol. 2024 Oct;21(10):725-742. doi: 10.1038/s41571-024-00932-9. Epub 2024 Aug 27. Nat Rev Clin Oncol. 2024. PMID: 39192001 Review.
Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.
Budczies J, Kluck K, Beck S, Ourailidis I, Allgäuer M, Menzel M, Kazdal D, Perkhofer L, Kleger A, Schirmacher P, Seufferlein T, Stenzinger A. Budczies J, et al. Among authors: beck s. J Pathol Clin Res. 2022 Jul;8(4):371-382. doi: 10.1002/cjp2.271. Epub 2022 Apr 5. J Pathol Clin Res. 2022. PMID: 35384413 Free PMC article.
Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors.
Menzel M, Kirchner M, Kluck K, Ball M, Beck S, Allgäuer M, Assmann C, Schnorbach J, Volckmar AL, Tay TKY, Goldschmid H, Tan DS, Thomas M, Kazdal D, Budczies J, Stenzinger A, Christopoulos P. Menzel M, et al. Among authors: beck s. J Pathol Clin Res. 2024 Mar;10(2):e354. doi: 10.1002/cjp2.354. J Pathol Clin Res. 2024. PMID: 38284983 Free PMC article.
Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD).
Rempel E, Kluck K, Beck S, Ourailidis I, Kazdal D, Neumann O, Volckmar AL, Kirchner M, Goldschmid H, Pfarr N, Weichert W, Hübschmann D, Fröhling S, Sutter C, Schaaf CP, Schirmacher P, Endris V, Stenzinger A, Budczies J. Rempel E, et al. Among authors: beck s. NPJ Precis Oncol. 2022 Jun 9;6(1):36. doi: 10.1038/s41698-022-00276-6. NPJ Precis Oncol. 2022. PMID: 35681079 Free PMC article.
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing.
Neumann O, Burn TC, Allgäuer M, Ball M, Kirchner M, Albrecht T, Volckmar AL, Beck S, Endris V, Goldschmid H, Lehmann U, Seker-Cin H, Uhrig S, Roessler S, Budczies J, Fröhling S, Longerich T, Wagner AH, Vogel A, Schirmacher P, Stenzinger A, Kazdal D. Neumann O, et al. Among authors: beck s. Br J Cancer. 2022 Nov;127(8):1540-1549. doi: 10.1038/s41416-022-01908-1. Epub 2022 Jul 23. Br J Cancer. 2022. PMID: 35871236 Free PMC article.
Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer.
Stögbauer F, Beck S, Ourailidis I, Hess J, Poremba C, Lauterbach M, Wollenberg B, Buchberger AMS, Jesinghaus M, Schirmacher P, Stenzinger A, Weichert W, Boxberg M, Budczies J. Stögbauer F, et al. Among authors: beck s. Br J Cancer. 2023 Jun;128(12):2295-2306. doi: 10.1038/s41416-023-02240-y. Epub 2023 Apr 12. Br J Cancer. 2023. PMID: 37045906 Free PMC article.
Correction: Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer.
Stögbauer F, Beck S, Ourailidis I, Hess J, Poremba C, Lauterbach M, Wollenberg B, Buchberger AMS, Jesinghaus M, Schirmacher P, Stenzinger A, Weichert W, Boxberg M, Budczies J. Stögbauer F, et al. Among authors: beck s. Br J Cancer. 2024 Feb;130(3):511. doi: 10.1038/s41416-023-02521-6. Br J Cancer. 2024. PMID: 38191610 Free PMC article. No abstract available.
Iron-Bound Lipocalin-2 Protects Renal Cell Carcinoma from Ferroptosis.
Meier JK, Schnetz M, Beck S, Schmid T, Dominguez M, Kalinovic S, Daiber A, Brüne B, Jung M. Meier JK, et al. Among authors: beck s. Metabolites. 2021 May 19;11(5):329. doi: 10.3390/metabo11050329. Metabolites. 2021. PMID: 34069743 Free PMC article.
2,014 results